Securities code: 603102 securities abbreviation: Baihe stock Announcement No.: 2022015 Weihai Baihe Biotechnology Co., Ltd
Announcement on main business data in the first quarter of 2022
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Weihai Baihe Biotechnology Co., Ltd. (hereinafter referred to as “the company”) hereby announces the main business data of the company in the first quarter of 2022 as follows in accordance with the relevant provisions of the guidelines for industrial information disclosure of listed companies No. 15 – food manufacturing (revised in 2020) of Shanghai Stock Exchange:
1、 Main business operation
(I) classification of main business by product category
Unit: Yuan
Product category: operating revenue in the first quarter of 2022
Soft capsule 6606795464
Tablet 3 Hangzhou First Applied Material Co.Ltd(603806) 206
Powder 1723733180
Hard capsule 1783367289
Functional drink 718072584
Combination and others 58157830
Total 144932553
(II) classification of main business by sales mode
Unit: Yuan
Sales model operating revenue in the first quarter of 2022
Contract production 11492040873
Independent brand Hainan Shennong Technology Co.Ltd(300189) 1680
Total 144932553
(III) classification of main business by Region
Unit: Yuan
Region’s operating revenue in the first quarter of 2022
Domestic 13120880039
Overseas 1373052514
Total 144932553
2、 Changes in the total number of major dealers
Unit: piece
Number of dealers at the end of the regional reporting period changes in the number of dealers at the beginning of the reporting period compared with the previous period
Domestic 377409 – 32
Overseas 2 – 2
Total 379409 – 30
The number of dealers at the end of the reporting period decreased by 32 compared with that at the beginning of the reporting period. The sales amount of the 32 withdrawn dealers accounted for only 0.56% of the current operating revenue in 2021, and the revenue accounted for a relatively small proportion. Therefore, the withdrawal of the 32 dealers will not have a significant adverse impact on the normal production and operation of the company.
3、 During the reporting period, there were no other events that had a significant impact on the company’s production and operation
The above operating data are only for investors to timely understand the company’s production and operation profile. The board of directors of the company reminds investors to use the above data carefully and pay attention to investment risks.
It is hereby announced.
Board of directors of Weihai Lily Biotechnology Co., Ltd. April 19, 2022
